샘플 요청 목록

 카트 문의
시장보고서
상품코드
1551560

CADD(Computer-Aided Drug Discovery) 시장

Computer-Aided Drug Discovery
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 375 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

CADD(Computer-Aided Drug Discovery) 세계 시장, 2030년까지 71억 달러에 달할 것으로 예상

2023년 36억 달러로 추정되는 CADD(Computer-Aided Drug Discovery) 세계 시장은 2023년부터 2030년까지 연평균 9.9% 성장하여 2030년에는 71억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 리간드 기반 설계는 CAGR 10.7%를 기록하여 분석 기간이 끝날 때까지 32억 달러에 도달할 것으로 예상됩니다. 구조 기반 설계 분야의 성장률은 분석 기간 동안 CAGR 9.5%로 추정됩니다.

미국 시장 9억 9,390만 달러로 추정, 중국은 CAGR 13.7%로 성장 전망

미국의 CADD(Computer-Aided Drug Discovery) 시장은 2023년 9억 9,390만 달러에 달할 것으로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 15억 달러 규모에 도달할 것으로 예상되며, 2023-2030년의 분석 기간 동안 13.7%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 7.3%와 8.5%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다. 유럽에서는 독일이 연평균 7.9%의 성장률을 보일 것으로 예상됩니다.

세계 CADD(Computer-Aided Drug Discovery) 시장 - 주요 동향 및 촉진요인 정리

CADD(Computer-Aided Drug Discovery)의 구조와 핵심기술은?

CADD(Computer-Aided Drug Discovery)(CADD)은 계산적 기법을 활용하여 기존에는 시간과 비용이 많이 소요되는 신약개발 과정을 가속화하고 정교화하는 최첨단 접근법입니다. 단백질, 효소 등 생물학적 표적과의 상호작용을 모델링하는 것입니다. 이 과정은 표적의 식별에서 시작하여 방대한 화합물 라이브러리를 스크리닝하고, 표적과 효과적으로 결합하고 그 활성을 조절할 수 있는 가능성을 분석하는 것으로 시작됩니다. 분자 도킹, 분자 동력학 시뮬레이션, 정량적 구조-활성 상관관계(QSAR) 모델링과 같은 기술은 이 과정에서 매우 중요한 역할을 합니다. 예를 들어, 분자 도킹은 약물 분자가 표적 부위에 어떻게 결합하는지를 예측하고, 분자 동력학 시뮬레이션은 약물과 표적의 복합체의 안정성과 시간 경과에 따른 거동에 대한 통찰력을 제공하며, QSAR 모델링은 화학 구조를 기반으로 화합물의 생물학적 활성을 예측하는 데 도움이 됩니다. 이러한 계산 도구는 신약 개발의 초기 단계를 효율화할 뿐만 아니라 약동학 및 독성 프로파일을 예측하여 리드 화합물의 최적화를 가능하게 하고, 궁극적으로 더 효과적이고 안전한 의약품을 생산할 수 있도록 돕습니다.

CADD(Computer-Aided Drug Discovery)의 혜택을 누리고 있는 사람은 누구이며, 어떻게 제약연구를 혁신하고 있는가?

CADD(Computer-Aided Drug Discovery)의 혜택은 제약업계, 학계, 연구기관, 그리고 궁극적으로 새로운 효과적인 치료법에 대한 신속한 접근을 통해 혜택을 받는 환자들에게까지 확대될 수 있습니다. 제약회사는 신약 출시에 막대한 자금과 시간적 압박을 받고 있지만, CADD가 제공하는 효율성을 통해 큰 이익을 얻을 수 있습니다. CADD는 대규모 실험실 실험의 필요성을 줄이고 수백만 개의 화합물을 신속하게 스크리닝할 수 있게 함으로써 유망한 신약 후보물질의 발굴을 가속화하고, 신약개발과 관련된 시간과 비용을 절감할 수 있습니다. 또한, 학계 연구자들은 CADD를 활용하여 새로운 치료 표적과 작용기전을 탐색하고, 기존 방법으로는 치료하기 어려웠던 질병에 대한 혁신적인 약물을 발견하고 있습니다. 환자들에게 CADD의 효과는 부작용이 적고 보다 표적화된 치료법의 형태로 나타납니다. 계산 모델링의 정확성은 건강한 세포와의 상호작용을 최소화하면서 질병을 유발하는 분자와 특이적으로 상호작용하도록 조정된 약물을 설계할 수 있기 때문입니다. 그 결과, CADD(Computer-Aided Drug Discovery)은 제약 산업을 변화시킬 뿐만 아니라, 보다 개인화되고 효과적인 헬스케어의 길을 열어가고 있습니다.

CADD(Computer-Aided Drug Discovery)의 최신 기술 혁신과 동향은?

CADD(Computer-Aided Drug Discovery) 분야는 빠르게 진화하고 있으며, 몇 가지 새로운 트렌드와 혁신이 제약 연구의 미래를 형성하고 있습니다. 가장 중요한 발전 중 하나는 인공지능(AI)과 머신러닝(ML)을 CADD 프로세스에 통합하는 것으로, AI 기반 알고리즘은 방대한 데이터 세트를 분석하고, 패턴을 식별하고, 전례 없는 정확도로 신약 후보물질의 활성을 예측할 수 있습니다. 이에 따라 신규 화합물 생성, 기존 화합물 최적화, 임상 결과 예측까지 자율적으로 수행하는 AI 기반 신약개발 플랫폼이 등장하고 있습니다. 또 다른 트렌드는 클라우드 컴퓨팅과 빅데이터 분석의 활용 확대입니다. 클라우드 컴퓨팅과 빅데이터 분석을 통해 연구자들은 분산 컴퓨팅의 힘을 활용하여 복잡한 시뮬레이션과 대규모 데이터 세트를 보다 효율적으로 분석할 수 있습니다. 양자컴퓨팅의 등장은 아직 초기 단계이지만, 원자 수준에서 분자 간 상호작용을 시뮬레이션할 수 있게 함으로써 CADD에 혁명을 일으키고 약물의 효능과 안전성을 보다 정확하게 예측할 수 있는 잠재력을 가지고 있습니다. 또한, 유전체학, 단백질체학, 대사체학 등 멀티오믹스 데이터의 활용은 CADD에서 점점 더 중요해지고 있으며, 질병 메커니즘에 대한 보다 종합적인 이해와 신약 타겟을 식별할 수 있게 해줍니다. 이러한 기술 혁신은 신약 개발의 가능성을 넓히고, 보다 신속하고 비용 효율적이며 정확한 치료법을 개발할 수 있도록 돕고 있습니다.

CADD(Computer-Aided Drug Discovery) 시장의 성장 원동력은?

CADD(Computer-Aided Drug Discovery) 시장의 성장은 제약 및 생명공학 산업의 지속적인 변화를 반영하는 몇 가지 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 질병 생물학의 복잡성으로 인해 신약개발에 더 정교한 도구가 필요하게 되었습니다는 점입니다. 암, 신경질환, 희귀 유전질환과 같은 질병에 대한 이해가 높아짐에 따라 이러한 복잡한 질병에 효과적으로 대응할 수 있는 표적치료제의 필요성이 증가하고 있습니다. 특히 AI, 머신러닝, 양자 컴퓨팅과 같은 기술 발전은 CADD를 더욱 강력하고 쉽게 사용할 수 있게 함으로써 업계 전반에서 CADD의 채택을 더욱 촉진하고 있으며, CADD는 신약 개발 프로세스를 간소화하고 그에 따른 재정적 위험을 완화하는 솔루션을 제공함으로써 의약품 개발 비용의 상승과 새로운 치료제 시장 출시 시간을 단축해야 한다는 압박도 큰 요인으로 작용하고 있습니다. 또한, 환자 개개인의 유전자 프로파일에 따라 맞춤형 치료법을 개발해야 하는 맞춤의료에 대한 관심이 높아지면서 특이성과 효능이 높은 의약품을 설계할 수 있는 CADD 기술에 대한 수요도 증가하고 있습니다. 제약사, 학계, 기술 제공업체 간의 협력 강화는 혁신을 촉진하고 CADD의 역량을 확대하는 데에도 기여하고 있습니다. 이러한 요인들이 복합적으로 작용하여 CADD(Computer-Aided Drug Discovery) 시장의 성장을 가속하고 미래 의료 발전의 중요한 원동력으로 자리매김하고 있습니다.

조사 대상 기업 예시(총 36건)

  • Bayer AG
  • Charles River Laboratories International, Inc.
  • ChemDiv, Inc.
  • Pharmaron Beijing Co.
  • BOC Sciences
  • Chemical Computing Group ULC
  • Curia Global, Inc.
  • Bioduro-Sundia
  • Aaranya Biosciences Pvt.
  • Aris Pharmaceuticals, Inc.

    목차

    제1장 조사 방법

    제2장 주요 요약

    • 시장 개요
    • 주요 기업
    • 시장 동향과 촉진요인
    • 세계 시장 전망

    제3장 시장 분석

    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 스페인
    • 러시아
    • 기타 유럽
    • 아시아태평양
    • 호주
    • 인도
    • 한국
    • 기타 아시아태평양
    • 라틴아메리카
    • 아르헨티나
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
    • 중동
    • 이란
    • 이스라엘
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동
    • 아프리카

    제4장 경쟁

    LSH 24.09.19

    Global Computer-Aided Drug Discovery Market to Reach US$7.1 Billion by 2030

    The global market for Computer-Aided Drug Discovery estimated at US$3.6 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2023-2030. Ligand-based Design, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$3.2 Billion by the end of the analysis period. Growth in the Structure-based Design segment is estimated at 9.5% CAGR over the analysis period.

    The U.S. Market is Estimated at US$993.9 Million While China is Forecast to Grow at 13.7% CAGR

    The Computer-Aided Drug Discovery market in the U.S. is estimated at US$993.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 13.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.3% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

    Global Computer-Aided Drug Discovery Market - Key Trends and Drivers Summarized

    How Does Computer-Aided Drug Discovery Work and What Are Its Core Technologies?

    Computer-aided drug discovery (CADD) is a cutting-edge approach that leverages computational methods to accelerate and refine the drug discovery process, traditionally a time-consuming and costly endeavor. At its core, CADD involves the use of sophisticated algorithms and simulations to model the interactions between potential drug candidates and biological targets, such as proteins or enzymes. The process begins with the identification of a target, followed by the screening of vast libraries of chemical compounds, which are analyzed for their potential to bind effectively with the target and modulate its activity. Technologies such as molecular docking, molecular dynamics simulations, and quantitative structure-activity relationship (QSAR) modeling play pivotal roles in this process. Molecular docking, for instance, predicts how a drug molecule will fit into a target site, while molecular dynamics simulations provide insights into the stability and behavior of the drug-target complex over time. QSAR modeling helps in predicting the biological activity of compounds based on their chemical structure. These computational tools not only streamline the early stages of drug discovery but also allow for the optimization of lead compounds by predicting their pharmacokinetic and toxicity profiles, ultimately leading to more effective and safer drugs.

    Who Benefits from Computer-Aided Drug Discovery and How Is It Transforming Pharmaceutical Research?

    The benefits of computer-aided drug discovery extend across the pharmaceutical industry, academic research institutions, and ultimately, patients who stand to gain from faster access to new and effective treatments. Pharmaceutical companies, faced with the immense financial and time pressures of bringing new drugs to market, benefit significantly from the efficiency gains offered by CADD. By reducing the need for extensive laboratory experimentation and enabling the rapid screening of millions of compounds, CADD accelerates the identification of promising drug candidates, reducing both the time and cost associated with drug development. Academic researchers also leverage CADD to explore novel therapeutic targets and mechanisms of action, often leading to the discovery of innovative drugs for conditions that have been challenging to treat with conventional methods. For patients, the impact of CADD is seen in the form of more targeted therapies with fewer side effects, as the precision of computational modeling allows for the design of drugs that are tailored to interact specifically with disease-causing molecules while minimizing interactions with healthy cells. As a result, computer-aided drug discovery is not only transforming the pharmaceutical landscape but also paving the way for more personalized and effective healthcare.

    What Are the Latest Innovations and Trends in Computer-Aided Drug Discovery?

    The field of computer-aided drug discovery is rapidly evolving, with several emerging trends and innovations shaping the future of pharmaceutical research. One of the most significant developments is the integration of artificial intelligence (AI) and machine learning (ML) into the CADD process. AI-driven algorithms are capable of analyzing vast datasets, identifying patterns, and predicting the activity of drug candidates with unprecedented accuracy. This has led to the emergence of AI-based drug discovery platforms that can autonomously generate novel compounds, optimize existing ones, and even predict clinical outcomes. Another trend is the increasing use of cloud computing and big data analytics, which allow researchers to harness the power of distributed computing to perform complex simulations and analyze large datasets more efficiently. The rise of quantum computing, though still in its early stages, holds the potential to revolutionize CADD by enabling the simulation of molecular interactions at an atomic level, leading to more accurate predictions of drug efficacy and safety. Additionally, the use of multi-omics data, including genomics, proteomics, and metabolomics, is becoming increasingly important in CADD, enabling a more comprehensive understanding of disease mechanisms and the identification of new drug targets. These innovations are pushing the boundaries of what is possible in drug discovery, leading to faster, more cost-effective, and more precise therapeutic development.

    What Is Driving the Growth of the Computer-Aided Drug Discovery Market?

    The growth in the computer-aided drug discovery market is driven by several factors that reflect the ongoing transformation of the pharmaceutical and biotechnology industries. One of the primary drivers is the increasing complexity of disease biology, which demands more sophisticated tools for drug discovery. As diseases like cancer, neurological disorders, and rare genetic conditions become better understood, there is a growing need for targeted therapies that can address these complex conditions effectively. Technological advancements, particularly in AI, machine learning, and quantum computing, are making CADD more powerful and accessible, further driving its adoption across the industry. The rising cost of drug development and the pressure to reduce time-to-market for new therapies are also significant factors, as CADD offers a solution that can streamline the drug discovery process and reduce the financial risks associated with it. Additionally, the growing focus on personalized medicine, which requires the development of therapies tailored to individual patients based on their genetic profiles, is fueling demand for CADD technologies that can design drugs with high specificity and efficacy. The increasing collaboration between pharmaceutical companies, academic institutions, and technology providers is also fostering innovation and expanding the capabilities of CADD. Together, these factors are propelling the growth of the computer-aided drug discovery market, positioning it as a key driver of future advancements in medicine.

    Select Competitors (Total 36 Featured) -

    • Bayer AG
    • Charles River Laboratories International, Inc.
    • ChemDiv, Inc.
    • Pharmaron Beijing Co., Ltd.
    • BOC Sciences
    • Chemical Computing Group ULC
    • Curia Global, Inc.
    • Bioduro-Sundia
    • Aaranya Biosciences Pvt. Ltd.
    • Aris Pharmaceuticals, Inc ;

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    • 1. MARKET OVERVIEW
      • Influencer Market Insights
      • Computer-Aided Drug Discovery - Global Key Competitors Percentage Market Share in 2024 (E)
      • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • 2. FOCUS ON SELECT PLAYERS
    • 3. MARKET TRENDS & DRIVERS
      • Rising Complexity of Disease Mechanisms Expands Addressable Market Opportunity for Advanced CADD Tools
      • Integration of Artificial Intelligence and Machine Learning Spurs Growth in Computer-Aided Drug Discovery Market
      • Advancements in High-Performance Computing Propel Adoption of Computer-Aided Drug Discovery Solutions
      • Increasing Use of Big Data Analytics in Drug Development Accelerates Demand for Computational Approaches
      • Emergence of Cloud-Based Solutions Expands Access to Computer-Aided Drug Discovery Resources
      • Rising Pressure to Reduce Drug Development Costs and Time-to-Market Sustains Growth in CADD Applications
      • Here's How Advances in Quantum Computing Are Poised to Revolutionize Computer-Aided Drug Discovery
    • 4. GLOBAL MARKET PERSPECTIVE
      • TABLE 1: World Computer-Aided Drug Discovery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
      • TABLE 2: World Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 3: World Historic Review for Computer-Aided Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 4: World 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
      • TABLE 5: World Recent Past, Current & Future Analysis for Ligand-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 6: World Historic Review for Ligand-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 7: World 16-Year Perspective for Ligand-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 8: World Recent Past, Current & Future Analysis for Structure-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 9: World Historic Review for Structure-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 10: World 16-Year Perspective for Structure-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 11: World Recent Past, Current & Future Analysis for Sequence-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 12: World Historic Review for Sequence-based Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 13: World 16-Year Perspective for Sequence-based Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 14: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 15: World Historic Review for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 16: World 16-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 17: World Recent Past, Current & Future Analysis for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 18: World Historic Review for Research Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 19: World 16-Year Perspective for Research Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 21: World Historic Review for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 22: World 16-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 23: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 24: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 25: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 26: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 27: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 28: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 29: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 30: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 31: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 32: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 33: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 34: World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
      • TABLE 35: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 36: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 37: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

    III. MARKET ANALYSIS

    • UNITED STATES
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
      • TABLE 38: USA Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 39: USA Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 40: USA 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 41: USA Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 42: USA Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 43: USA 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 44: USA Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 45: USA Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 46: USA 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • CANADA
      • TABLE 47: Canada Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 48: Canada Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 49: Canada 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 50: Canada Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 51: Canada Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 52: Canada 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 53: Canada Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 54: Canada Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 55: Canada 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • JAPAN
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
      • TABLE 56: Japan Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 57: Japan Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 58: Japan 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 59: Japan Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 60: Japan Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 61: Japan 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 62: Japan Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 63: Japan Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 64: Japan 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • CHINA
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
      • TABLE 65: China Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 66: China Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 67: China 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 68: China Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 69: China Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 70: China 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 71: China Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 72: China Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 73: China 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • EUROPE
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
      • TABLE 74: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 75: Europe Historic Review for Computer-Aided Drug Discovery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 76: Europe 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
      • TABLE 77: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 78: Europe Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 79: Europe 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 80: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 81: Europe Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 82: Europe 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 83: Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 84: Europe Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 85: Europe 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • FRANCE
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
      • TABLE 86: France Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 87: France Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 88: France 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 89: France Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 90: France Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 91: France 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 92: France Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 93: France Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 94: France 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • GERMANY
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
      • TABLE 95: Germany Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 96: Germany Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 97: Germany 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 98: Germany Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 99: Germany Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 100: Germany 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 101: Germany Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 102: Germany Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 103: Germany 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • ITALY
      • TABLE 104: Italy Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 105: Italy Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 106: Italy 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 107: Italy Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 108: Italy Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 109: Italy 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 110: Italy Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 111: Italy Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 112: Italy 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • UNITED KINGDOM
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
      • TABLE 113: UK Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 114: UK Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 115: UK 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 116: UK Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 117: UK Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 118: UK 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 119: UK Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 120: UK Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 121: UK 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • SPAIN
      • TABLE 122: Spain Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 123: Spain Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 124: Spain 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 125: Spain Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 126: Spain Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 127: Spain 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 128: Spain Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 129: Spain Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 130: Spain 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • RUSSIA
      • TABLE 131: Russia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 132: Russia Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 133: Russia 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 134: Russia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 135: Russia Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 136: Russia 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 137: Russia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 138: Russia Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 139: Russia 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • REST OF EUROPE
      • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 141: Rest of Europe Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 142: Rest of Europe 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 144: Rest of Europe Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 145: Rest of Europe 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 147: Rest of Europe Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 148: Rest of Europe 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • ASIA-PACIFIC
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
      • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 150: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 151: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
      • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 153: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 154: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 156: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 157: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 159: Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 160: Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • AUSTRALIA
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
      • TABLE 161: Australia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 162: Australia Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 163: Australia 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 164: Australia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 165: Australia Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 166: Australia 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 167: Australia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 168: Australia Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 169: Australia 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • INDIA
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
      • TABLE 170: India Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 171: India Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 172: India 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 173: India Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 174: India Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 175: India 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 176: India Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 177: India Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 178: India 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • SOUTH KOREA
      • TABLE 179: South Korea Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 180: South Korea Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 181: South Korea 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 182: South Korea Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 183: South Korea Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 184: South Korea 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 185: South Korea Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 186: South Korea Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 187: South Korea 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • REST OF ASIA-PACIFIC
      • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 189: Rest of Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 192: Rest of Asia-Pacific Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 195: Rest of Asia-Pacific Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • LATIN AMERICA
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
      • TABLE 197: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 198: Latin America Historic Review for Computer-Aided Drug Discovery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 199: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
      • TABLE 200: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 201: Latin America Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 202: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 203: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 204: Latin America Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 205: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 206: Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 207: Latin America Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 208: Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • ARGENTINA
      • TABLE 209: Argentina Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 210: Argentina Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 211: Argentina 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 212: Argentina Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 213: Argentina Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 214: Argentina 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 215: Argentina Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 216: Argentina Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 217: Argentina 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • BRAZIL
      • TABLE 218: Brazil Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 219: Brazil Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 220: Brazil 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 221: Brazil Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 222: Brazil Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 223: Brazil 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 224: Brazil Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 225: Brazil Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 226: Brazil 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • MEXICO
      • TABLE 227: Mexico Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 228: Mexico Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 229: Mexico 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 230: Mexico Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 231: Mexico Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 232: Mexico 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 233: Mexico Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 234: Mexico Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 235: Mexico 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • REST OF LATIN AMERICA
      • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 237: Rest of Latin America Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 238: Rest of Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 240: Rest of Latin America Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 241: Rest of Latin America 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 243: Rest of Latin America Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 244: Rest of Latin America 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • MIDDLE EAST
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
      • TABLE 245: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
      • TABLE 246: Middle East Historic Review for Computer-Aided Drug Discovery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 247: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
      • TABLE 248: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 249: Middle East Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 250: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 251: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 252: Middle East Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 253: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 254: Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 255: Middle East Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 256: Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • IRAN
      • TABLE 257: Iran Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 258: Iran Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 259: Iran 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 260: Iran Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 261: Iran Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 262: Iran 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 263: Iran Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 264: Iran Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 265: Iran 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • ISRAEL
      • TABLE 266: Israel Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 267: Israel Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 268: Israel 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 269: Israel Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 270: Israel Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 271: Israel 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 272: Israel Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 273: Israel Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 274: Israel 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • SAUDI ARABIA
      • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 276: Saudi Arabia Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 277: Saudi Arabia 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 279: Saudi Arabia Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 280: Saudi Arabia 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 282: Saudi Arabia Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 283: Saudi Arabia 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • UNITED ARAB EMIRATES
      • TABLE 284: UAE Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 285: UAE Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 286: UAE 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 287: UAE Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 288: UAE Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 289: UAE 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 290: UAE Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 291: UAE Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 292: UAE 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • REST OF MIDDLE EAST
      • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 294: Rest of Middle East Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 295: Rest of Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 297: Rest of Middle East Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 298: Rest of Middle East 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 300: Rest of Middle East Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 301: Rest of Middle East 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030
    • AFRICA
      • Computer-Aided Drug Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
      • TABLE 302: Africa Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 303: Africa Historic Review for Computer-Aided Drug Discovery by Design type - Ligand-based Design, Structure-based Design and Sequence-based Design Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 304: Africa 16-Year Perspective for Computer-Aided Drug Discovery by Design type - Percentage Breakdown of Value Sales for Ligand-based Design, Structure-based Design and Sequence-based Design for the Years 2014, 2024 & 2030
      • TABLE 305: Africa Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 306: Africa Historic Review for Computer-Aided Drug Discovery by End-Use - Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 307: Africa 16-Year Perspective for Computer-Aided Drug Discovery by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Research Laboratories End-Use and Pharmaceutical Companies End-Use for the Years 2014, 2024 & 2030
      • TABLE 308: Africa Recent Past, Current & Future Analysis for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
      • TABLE 309: Africa Historic Review for Computer-Aided Drug Discovery by Therapeutic Area - Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
      • TABLE 310: Africa 16-Year Perspective for Computer-Aided Drug Discovery by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurology, Diabetes, Cardiovascular Disease and Other Therapeutic Areas for the Years 2014, 2024 & 2030

    IV. COMPETITION

    • 샘플 요청 목록
    0 건의 상품을 선택 중
    목록 보기
    전체삭제